Treatment for clinical schistosomiasis has relied centrally on the broad spectrum anthelmintic praziquantel; however, there is limited information on its mode of action or the molecular response of the parasite. This paper presents a transcriptional and functional approach to defining the molecular responses of schistosomes to praziquantel. Differential gene expression in Schistosoma japonicum ...

The purpose of the research is to develop and test new dosage forms against bothriocephalosis cyprinids. Materials methods . study was performed in experimental therapy laboratory VNIIP – FSC VIEV, on a cage fish farm Cherepetsky Rybkhoz JSC (Suvorov, Tula Region). A formulation developed for two micronized albendazole praziquantel prevent treat cestodosis fish, namely, praziquantel. For experi...

BACKGROUND Both tribendimidine and mebendazole are broad-spectrum drugs for anti-intestinal nematodes. We aim to assess the efficacy and safety of tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths. METHOD We performed a randomized open-label trial in Qiyang, People's Republic of China. Eligible participants were randomly assigned to one of...

Despite extensive use of praziquantel, the current drug of choice for the treatment of schistosomiasis and other helminthic infections, little information is available about its pharmacokinetics in individuals living in geographic areas where such infections are endemic. We investigated the pharmacokinetics of praziquantel by determining its serum concentration-time course in four selected Fili...

BACKGROUND Chemotherapy for schistosomiasis has been around for 100 years. During the past century, great efforts have been made to develop new antischistosomal drugs from antimonials to nonantimonials, and some of these have been used extensively in clinical treatment. With the exception of a few drugs, such as oxamniquine and metrifonate, most of the antischistosomals developed in the pre-pra...

background praziquantel, an antischistosomal compound, is used as first-line drug for chemotherapy of schistosoma japonicum since 1984. in this article, we conducted a systematic review and mete-analysis to evaluate the efficacy and safety of different dosages of praziquantel (pzq) for treatment of schistosoma japonicum. evidence acquisition: a number of six articles published in peer-reviewed ...

Abstract Schistosomiasis, a neglected tropical disease, affects millions of lives and accounts for thousands deaths each year. The Schistosoma parasites depend on two hosts during their lifecycle: snails as intermediate human beings definitive hosts. Therefore, to control ultimately eliminate schistosomiasis relies the reduction snail populations well prevention treatment infections. Praziquant...

BACKGROUND Mass drug administration of praziquantel is the World Health Organization's endorsed control strategy for schistosomiasis. A decade of annual treatments across sub-Saharan Africa has resulted in significant reductions of infection prevalence and intensity levels, although 'hotspots' remain. Repeated drug treatments place strong selective pressures on parasites, which may affect life-...

Symptomatic intraventricular cysticerci are said to respond poorly to the anticestodial agent praziquantel. A case is reported of rapid regression of a large cyst of the fourth ventricle after oral praziquantel, avoiding the need for surgery.

This paper summarizes and concludes in-depth field investigations on suspected resistance of Schistosoma mansoni to praziquantel in northern Senegal. Praziquantel at 40 mg/kg usually cures 70-90% of S. mansoni infections. In an initial trial in an epidemic S. mansoni focus in northern Senegal, only 18% of the cases became parasitologically negative 12 weeks after treatment, although the reducti...